Suchergebnisse - "Vijgen, Leen"

PubPharm (91)

1

CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus

enthalten in: Paediatric drugs | 2024

von Ferrero, F. | Lin, C. | Liese, J. | +19

2

A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Nilsson, A. | Pullman, J. | Napora, P. | +15

3

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis : the Phase IIa OMEGA-3 study

enthalten in: Journal of gastroenterology | 2020

von Takehara, T. | Chayama, K. | Kurosaki, M. | +14

4

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients : Long-term follow-up results from the open-label, Phase II IMPACT study

enthalten in: Health science reports | 2020

von Lawitz, E. | Poordad, F. | Gutierrez, J. | +8

5

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study

enthalten in: Journal of gastroenterology | 2020

von Takehara, T. | Chayama, K. | Kurosaki, M. | +14

6

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study

enthalten in: Journal of gastroenterology | 2020

von Takehara, T. | Chayama, K. | Kurosaki, M. | +14

7

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study

enthalten in: Journal of gastroenterology | 2020

von Takehara, T. | Chayama, K. | Kurosaki, M. | +14

8

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients : Long‐term follow‐up results from the open‐label, Phase II IMPACT study

enthalten in: Health Science Reports | 2020

von Lawitz, E. | Poordad, F. | Gutierrez, J. | +8

9

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis : OMEGA-1

enthalten in: Hepatology (Baltimore, Md.) | 2019

von Zeuzem, S. | Bourgeois, S. | Greenbloom, S. | +19

10

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis : OMEGA‐1

enthalten in: Hepatology | 2019

von Zeuzem, S. | Bourgeois, S. | Greenbloom, S. | +18

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]